Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

作者：Miranda K. Branyiczky, Megan S. Lowe, Eric McMullen, Jeffrey Donovan, Touraj Khosravi‐Hafshejani · 发表于：International Journal of Dermatology · 年份：2025 · DOI：10.1111/ijd.70133 · 被引用次数：5 · 研究领域：Hair Growth and Disorders、Diabetes Treatment and Management、Pain Mechanisms and Treatments

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for metabolic disorders, including type 2 diabetes mellitus (T2DM) and obesity. Reports to date have documented hair loss as an adverse event, while cases of hair regrowth have also been described [1]. This review evaluates evidence linking GLP-1RA use to hair outcomes. Following PRISMA guidelines, Embase and MEDLINE were searched (from inception to July 2025) using keywords specific to GLP-1RAs, “alopecia,” and “hair regrowth” (PROSPERO: CRD420251104356). Of 485 records identified, 10 full-text studies were included, comprising three retrospective cohort studies, four retrospective pharmacovigilance database studies, one living benefit-harm modeling study, one case–control study, and one case report. Risk of bias was assessed using Joanna Briggs critical appraisal tools. Hair loss type was mostly unspecified; however, 82 patients had centrifugal cicatricial alopecia (CCCA), 20 had androgenic alopecia (AGA), and 10 had telogen effluvium. Pharmacovigilance and modeling analyses examined a total of 920,890 adverse events, while cohort studies involved 382 patients. GLP-1RAs investigated included exenatide (27.1%, 170,880/630,671), dulaglutide (23.4%, 147,624/630,671), liraglutide (21.4%, 135,178/630,671), semaglutide (11.3%, 71,528/630,671), and tirzepatide (9.9%, 62,196/630,671). Of 626,894 patients on GLP-1RA for whom hair outcomes were reported, 9933 (1.6%) experienced hair loss, whereas 52 (0.008%) r...